Published on

Medicine – Hodgkin Lymphoma

Hodgkin lymphoma (HL) is a malignant lymphoid neoplasm characterised by the presence of Reed–Sternberg cells in an appropriate inflammatory cellular background.

It is predominantly a B-cell-derived lymphoma and commonly presents with painless lymphadenopathy, particularly involving cervical, supraclavicular and mediastinal lymph nodes.

Unlike many non-Hodgkin lymphomas, Hodgkin lymphoma often spreads in a relatively predictable, contiguous pattern between adjacent lymph node groups.

Important Clinical Principle

Hodgkin lymphoma is a potentially curable lymphoid malignancy. Classical Hodgkin lymphoma is characterised by Hodgkin/Reed–Sternberg cells, usually expressing CD15 and CD30.

1. Classification

Hodgkin lymphoma has traditionally been divided into classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma.

Classification Characteristics
Classical Hodgkin lymphoma (cHL) Approximately 90–95% of cases; characteristic Reed–Sternberg cells, usually CD15+ and CD30+
Nodular lymphocyte-predominant disease LP or “popcorn” cells; typically CD20+ and CD45+, usually CD15− and CD30−
Classification Update: The WHO fifth edition classifies nodular lymphocyte-predominant disease as nodular lymphocyte-predominant B-cell lymphoma, whereas the International Consensus Classification retains the term nodular lymphocyte-predominant Hodgkin lymphoma.

Classical Hodgkin Lymphoma Subtypes

  • Nodular sclerosis: Common subtype, often associated with mediastinal disease.
  • Mixed cellularity: Reed–Sternberg cells in a mixed inflammatory background.
  • Lymphocyte-rich: Numerous reactive lymphocytes with relatively few malignant cells.
  • Lymphocyte-depleted: Rare subtype with relatively few background lymphocytes.

2. Pathophysiology

Classical Hodgkin lymphoma develops from abnormal germinal-centre B cells.

The malignant Hodgkin/Reed–Sternberg cells usually represent only a minority of cells within the tumour. They are surrounded by reactive lymphocytes, eosinophils, macrophages and other inflammatory cells.

Cytokines and chemokines released by the malignant cells recruit inflammatory cells and contribute to lymph node enlargement and systemic symptoms.

Pathophysiology Flowchart

Abnormal Germinal-Centre B Cell Hodgkin / Reed–Sternberg Cells Cytokine Release Inflammatory cell recruitment Clinical Manifestations Painless lymphadenopathy Fever / night sweats / weight loss Other systemic manifestations

3. Reed–Sternberg Cells

Reed–Sternberg cells are large abnormal cells that may contain two nuclei or a bilobed nucleus with prominent eosinophilic nucleoli.

The classical appearance is often described as an “owl's-eye” appearance.

Schematic of a Reed–Sternberg Cell

Nucleus Prominent nucleolus Cytoplasm Classical Reed–Sternberg Cell

Simplified educational illustration; not a histological image.

Characteristic Features

  • Large binucleated or multinucleated cells.
  • Prominent eosinophilic nucleoli.
  • Classical “owl's-eye” appearance.
  • Usually positive for CD30 and CD15 in classical Hodgkin lymphoma.
  • Usually negative or weakly positive for CD20, with weak PAX5 expression.
Examination Pearl: Reed–Sternberg-like cells may also occur in other disorders. Definitive diagnosis requires the appropriate tissue architecture, inflammatory background and immunophenotype.

4. Clinical Features

A. Painless Lymphadenopathy

The most common presentation is painless lymph node enlargement.

Approximately 80% of patients have lymphadenopathy above the diaphragm at presentation.

Commonly affected sites include:

  • Cervical lymph nodes.
  • Supraclavicular lymph nodes.
  • Mediastinal lymph nodes.
  • Axillary lymph nodes.

B. B Symptoms

B symptoms may occur in approximately 30–40% of patients, although their frequency varies by stage and population.

B Symptom Definition
FeverUnexplained temperature above 38°C
Night sweatsDrenching night sweats
Weight lossUnintentional loss of more than 10% of body weight within six months

C. Alcohol-Induced Lymph Node Pain

Pain at sites of involved lymph nodes following alcohol consumption is an unusual but classically associated feature of Hodgkin lymphoma.

It occurs in a small minority of patients, traditionally reported in fewer than 10%, and is not sufficiently sensitive or specific to establish the diagnosis.

D. Pel–Ebstein Fever

Pel–Ebstein fever is a historically described cyclical fever pattern consisting of:

  • Febrile episodes lasting approximately 1–2 weeks.
  • Alternating afebrile periods lasting approximately 1–2 weeks.

Its occurrence and diagnostic specificity are uncertain, and it has limited diagnostic value in modern clinical practice.

E. Hepatosplenomegaly

Hepatomegaly and splenomegaly may occur, particularly in advanced disease.

F. Other Manifestations

  • Pruritus.
  • Fatigue.
  • Chest discomfort.
  • Cough or dyspnoea due to mediastinal lymphadenopathy.
  • Rarely, superior vena cava obstruction.
  • Cytopenias in advanced disease or with bone marrow involvement.

5. Investigations

A. Lymph Node Biopsy

Excisional lymph node biopsy is preferred when feasible.

Histopathological examination identifies the characteristic malignant cells and inflammatory background, while immunohistochemistry establishes the lymphoma subtype.

B. Blood Investigations

Investigation Possible Finding
Full blood countAnaemia, leukocytosis, lymphopenia or eosinophilia
ESRMay be elevated; useful in selected risk assessments
LDHMay be elevated but is nonspecific
Liver functionMay be abnormal with hepatic involvement or other causes
Renal functionBaseline assessment before treatment
Infection screeningHIV and hepatitis testing as indicated before therapy

C. Imaging

FDG-PET/CT is the preferred staging investigation for most patients with classical Hodgkin lymphoma.

It identifies nodal and extranodal involvement and is useful for assessing treatment response.

D. Bone Marrow Examination

Routine bone marrow biopsy is generally not required when adequate PET/CT staging is available for classical Hodgkin lymphoma.

It may be considered in selected circumstances where findings are uncertain or alternative diagnoses are suspected.

Diagnostic Flowchart

Suspected Hodgkin Lymphoma Painless nodes / B symptoms Lymph Node Biopsy Excision preferred when feasible Histopathology Reed–Sternberg cells / immunophenotype Staging Investigations FDG-PET/CT and clinical assessment Treatment Planning Stage, bulk, risk and fitness Guide individualised therapy

6. Ann Arbor / Lugano Staging

Hodgkin lymphoma is staged according to the anatomical distribution of disease, commonly using the Lugano classification based on the Ann Arbor system.

Stage Description
ISingle lymph node region or a single localized extranodal site
IITwo or more lymph node regions on the same side of the diaphragm
IIILymph node regions on both sides of the diaphragm
IVDiffuse or disseminated extranodal involvement, such as liver, bone marrow or lungs

A and B Suffixes

  • A: Absence of B symptoms.
  • B: Presence of one or more B symptoms.

For example, stage IIB indicates involvement of two or more lymph node regions on the same side of the diaphragm, with B symptoms.

Bulky disease and other clinical risk factors are also important when selecting treatment.

Staging Diagram

Stage I One lymph node region Diaphragm Stage II Same side of diaphragm Diaphragm Stage III Both sides of diaphragm Diaphragm Stage IV Disseminated extranodal disease Schematic organ involvement

Simplified conceptual diagram; not an anatomical staging image.

7. Management of Hodgkin Lymphoma

Hodgkin lymphoma is frequently curable, including in many patients with advanced disease.

Treatment depends on stage, disease bulk, risk factors, patient fitness and interim PET response.

A. Early-Stage Disease

Treatment options may include:

  • Combination chemotherapy.
  • Involved-site radiotherapy in selected patients.
  • PET-adapted treatment strategies.

B. Advanced-Stage Disease

Systemic combination therapy is the mainstay of treatment.

Regimens may include:

  • ABVD: Doxorubicin, bleomycin, vinblastine and dacarbazine.
  • Nivolumab-AVD: A contemporary option for eligible patients with advanced classical Hodgkin lymphoma where approved and available.
  • Brentuximab vedotin plus AVD: Another option in selected patients.
  • Escalated BEACOPP or related intensive regimens: Used selectively in certain protocols.

The optimal regimen depends on patient characteristics, clinical guidelines and local availability.

C. Relapsed or Refractory Disease

Treatment options include:

  • Salvage systemic therapy.
  • Autologous stem cell transplantation in eligible patients.
  • Brentuximab vedotin.
  • PD-1 inhibitors, including nivolumab or pembrolizumab.
  • Other specialised therapies.

D. Supportive Care and Follow-Up

  • Management of treatment-related infections and cytopenias.
  • Fertility preservation counselling when appropriate.
  • Monitoring for cardiopulmonary toxicity.
  • Assessment for late effects, including second malignancies and cardiovascular disease.

Treatment Flowchart

Confirmed Hodgkin Lymphoma PET/CT staging and risk assessment Early-Stage Disease Limited anatomical spread Advanced-Stage Disease Extensive disease Management Options Combination chemotherapy Selected-site radiotherapy PET-adapted strategies Management Options Systemic combination therapy Immunotherapy-based options Response-guided care Response and Follow-Up

8. Hodgkin vs Non-Hodgkin Lymphoma

Feature Hodgkin Lymphoma Non-Hodgkin Lymphoma
Characteristic cellsReed–Sternberg cells in classical HLVariable malignant lymphoid cells
Cellular originUsually germinal-centre B cellsB, T or NK cells
SpreadOften contiguousOften less predictable
Mediastinal involvementCommon in some subtypesVariable
Extranodal involvementLess common at presentationMore common in many subtypes
TreatmentSystemic therapy ± radiotherapyHighly subtype-dependent
PrognosisFrequently curableVaries widely by subtype

9. High-Yield Examination Summary

Feature Key Point
DiseaseB-cell-derived lymphoid malignancy
Characteristic cellReed–Sternberg cell
Classical immunophenotypeCD15+, CD30+, weak PAX5+
Common presentationPainless cervical or supraclavicular lymphadenopathy
DistributionFrequently above the diaphragm
B symptomsFever, night sweats, weight loss
Classical associated featureAlcohol-induced nodal pain
Historical fever patternPel–Ebstein fever
DiagnosisExcisional lymph node biopsy when feasible
StagingFDG-PET/CT with Lugano classification
TreatmentCombination systemic therapy ± radiotherapy
PrognosisOften curable

10. Key Examination Pearls

  • Reed–Sternberg cells are characteristic of classical Hodgkin lymphoma.
  • Classical Hodgkin lymphoma is a B-cell-derived malignancy.
  • Painless cervical or supraclavicular lymphadenopathy is a common presentation.
  • Mediastinal lymphadenopathy is particularly associated with nodular sclerosis classical HL.
  • B symptoms are unexplained fever, drenching night sweats and weight loss exceeding 10% over six months.
  • Alcohol-induced nodal pain is uncommon but classically associated with Hodgkin lymphoma.
  • Pel–Ebstein fever is a historical description and has limited diagnostic utility.
  • Excisional lymph node biopsy is preferred for diagnosis.
  • FDG-PET/CT is central to staging and response assessment.
  • Bone marrow biopsy is usually unnecessary when adequate PET/CT staging is available.
  • Hodgkin lymphoma is often curable with modern treatment.
Most Important Examination Point

A patient with persistent painless cervical lymphadenopathy, mediastinal lymph node enlargement and B symptoms should raise suspicion of Hodgkin lymphoma. Diagnosis requires tissue biopsy demonstrating the characteristic pathology and immunophenotype.

Clinical Note

Rapidly progressive chest symptoms, airway compromise or suspected superior vena cava obstruction require urgent medical assessment. Treatment should be individualised by a specialist haematology team.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments